SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff--Schering-Plough Corporation (JOBS) Antipsychotic Works

July 28, 2009 | 
1 min read

Reuters - Schering-Plough Corp’s (SGP.N) experimental antipsychotic drug Saphris works and appears as safe as other similar medications, U.S. Food and Drug Administration staff said in a memo released on Tuesday.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac